Omlonti for Glaucoma
Glaucoma prevalence increases with age. The FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. These eye drops reduce the amount of fluid in the eye, lowering intraocular pressure.
Omlonti is a selective prostaglandin EP2 receptor agonist. It increases aqueous humor drainage through the conventional and uveoscleral outflow pathways. It is the only product with this action. The medication is administered as one drop per day in the affected eye.
Adverse effects of Omlonti include cystoid macular edema, particularly in patients with aphakia or pseudophakia, or those with other risk factors. Other side effects include intraocular inflammation, increased iris pigmentation, and changes in eyelashes.
As with any medication, follow your eyecare provider’s instructions carefully. Inform your provider of any other medications or medical conditions before starting treatment with Omlonti.
https://www.santen.com/content/dam/santen/global/pdf/en/news/20220926-1.pdf
